Latest Philadelphia chromosome Stories
MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy.
Two drugs approved for treatment of drug-resistant chronic myeloid leukemia provide patients with quicker, better responses as a first therapy than the existing front-line medication.
EAST HANOVER, N.J., June 4 /PRNewswire/ -- Novartis announced today 18-month results (median follow-up) showing that TasignaÂ® (nilotinib) capsules significantly surpass the efficacy of GleevecÂ® (imatinib mesylate) tablets* in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase(1).
New research discovers a combination of drugs that may prove to be a more effective treatment for a lethal form of leukemia.
An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells.
EAST HANOVER, N.J., Feb.
FRIMLEY, England, December 8 /PRNewswire/ -- - Nilotinib Surpassed imatinib in Key Measures of Treatment Effectiveness in the Trial, in Patients With Newly-Diagnosed Disease(1) - At 12-Months, Significantly Fewer Patients Progressed to Later Stages of the Disease on nilotinib (300mg Twice-Daily and 400mg Twice-Daily) Than on imatinib 400mg Once-Daily(1) - Nilotinib was Generally Well Tolerated; Only a Small Number of Patients Discontinued Due to Adverse Events(1) -...
EAST HANOVER, N.J., Dec.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug.
Leukemia and myeloproliferative disorders are serious and often deadly blood cancers.
- Withering but not falling off, as a blossom that persists on a twig after flowering.